# Long-term Safety and Performance of KiOmedine CM-Chitosan Supplementation in Advanced Symptomatic Knee Osteoarthritis

> **NCT05214807** · PHASE4 · UNKNOWN · sponsor: **Kiomed Pharma** · enrollment: 104 (actual)

## Conditions studied

- Osteoarthritis, Knee

## Interventions

- **DEVICE:** KiOmedine® CM-Chitosan
- **DEVICE:** Synvisc-One®

## Key facts

- **NCT ID:** NCT05214807
- **Lead sponsor:** Kiomed Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-26
- **Primary completion:** 2023-08-20
- **Final completion:** 2024-02-20
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2023-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05214807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05214807, "Long-term Safety and Performance of KiOmedine CM-Chitosan Supplementation in Advanced Symptomatic Knee Osteoarthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05214807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*